Finding the right medication for rheumatoid arthritis isn't easy, and a newer pill against the disease carries higher risks of heart attack, stroke and cancer than older RA drugs, a new clinical trial ...

Patients with rheumatoid arthritis (RA) tolerated a novel Janus kinase/Roh-associated protein kinase (JAK-ROCK) inhibitor without typical side effects. Phase 2 clinical trial at nine hospitals and ...

The reports suggest patients with rheumatoid arthritis (RA) could experience secondary neurological adverse events, though the side effect appears to be rare. A new report suggests patients who are ...

Patients with rheumatoid arthritis (RA) treated with Janus kinase (JAK) inhibitors showed no increased incidence of major adverse cardiovascular events (MACEs) compared with those treated with tumour ...

The FDA updated the indication of the JAK inhibitor upadacitinib (Rinvoq) in inflammatory bowel disease (IBD) to account for ...

PHILADELPHIA — Patients with rheumatoid arthritis frequently switched between JAK inhibitors in Australia, according to a presentation at ACR Convergence 2022. “JAK inhibitors and biologics are ...

In a single-arm RAMUS study, JAK inhibition with tofacitinib increased lower limb muscle volume without measurable strength ...

Newco Elevara Medicines Ltd. has raised $70 million in a series A to fund a phase IIa/IIb trial of ELV-001, a first-in-class, ...

Please provide your email address to receive an email when new articles are posted on . JAK inhibition carried higher malignancy risk vs. biologic DMARDs. Malignancy risk was seen in older patients ...

BOSTON--(BUSINESS WIRE)--DeepCure, a therapeutics company using AI to discover novel drugs for inflammation and immune diseases, will present new in vivo data demonstrating its selective BRD4 (BD2) ...